Myeloperoxidase Mass (MPO)
This biomarker measures the concentration of myeloperoxidase, an enzyme released by white blood cells, in the blood to assess cardiovascular inflammation and risk.
MPO mass assesses cardiovascular inflammation and risk.
Key facts at a glance
- Units
- ng/mL
- Clinical utility
- diagnostic
- Result kind
- quantitative
- FDA-cleared
- Abbott MPO, Roche MPO
Myeloperoxidase (MPO) is an enzyme found in white blood cells that plays a crucial role in the immune response and is released during inflammation. Elevated levels of MPO mass in the blood can indicate increased inflammation and oxidative stress, which are associated with cardiovascular diseases.
The measurement of MPO mass is used as a diagnostic tool to evaluate the risk of cardiovascular events, such as heart attacks and strokes. It provides additional information to traditional risk factors and can help in early intervention and prevention strategies.
Normal reference ranges for MPO mass are typically between 0–530 ng/mL. Levels above this range may suggest heightened cardiovascular risk and warrant further clinical evaluation.
Frequently asked questions
What does a high MPO mass level mean?
How is MPO mass measured?
Sources
- 1
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy